EVerZom Secures €10M to Advance Groundbreaking Exosome-Based Biotherapies for Inflammatory Diseases
EVerZom, a pioneering biotechnology firm based in France, has secured €10 million in a Series A funding round to propel the clinical development of its first therapeutic candidate and further scale its exosome biomanufacturing platform. The investment, which brings together major players like Capital Grand Est, the European Innovation Council (EIC) Fund, Sorbonne Venture by…
